Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
33.9 SEK | -1.74% | +12.62% | -34.81% |
May. 15 | Genovis AB (publ.) Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Mar. 14 | Carthesian Therapeutics Terminates Genovis AB (Publ.) Licence Agreement | CI |
Business Summary
Number of employees: 37
Sales per Business
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Enzyme
87.6
%
| 85 | 83.1 % | 139 | 87.6 % | +62.88% |
Antibodies
12.4
%
| 17 | 16.9 % | 20 | 12.4 % | +13.45% |
Sales per region
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Other Countries
99.5
%
| 102 | 99.4 % | 157 | 99.5 % | +54.72% |
Sweden
0.5
%
| 1 | 0.6 % | 1 | 0.5 % | +25.91% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Fredrik Olsson
CEO | Chief Executive Officer | 53 | 01-12-31 |
Magnus Långberg
DFI | Director of Finance/CFO | 53 | 21-12-31 |
Rolf Lood
CTO | Chief Tech/Sci/R&D Officer | 40 | 16-12-31 |
Susanne Ahlberg
IRC | Investor Relations Contact | 67 | 06-12-31 |
Rikke Rytter
SAM | Sales & Marketing | 57 | 20-12-31 |
Jonathan Sjögren
PRN | Corporate Officer/Principal | 39 | 13-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 72 | 20-05-04 | |
Director/Board Member | 63 | 18-12-31 | |
Mikael Lönn
BRD | Director/Board Member | 75 | 13-12-31 |
Director/Board Member | 52 | 21-12-31 | |
Steve Jordan
BRD | Director/Board Member | 71 | 20-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 65,465,714 | 62,469,000 ( 95.42 %) | 0 | 95.42 % |
Company contact information
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.81% | 211M | |
-4.42% | 12.33B | |
-4.35% | 8.14B | |
+30.81% | 5.62B | |
-7.42% | 4.24B | |
-54.27% | 3.06B | |
+14.44% | 2.76B | |
-1.69% | 2.41B | |
+28.53% | 2.23B | |
-4.67% | 1.87B |
- Stock Market
- Equities
- GENO Stock
- Company Genovis AB